Companies › Aktis Oncology
3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [225Ac]Ac-AKY-1189 Nectin-4 targeted alpha-emitting radiopharmaceutical | NECTIN4 | Phase 1 | Urothelial Carcinoma Bladder | Dec 2027 |
| [225Ac]Ac-AKY-2519 | – | Phase 1 | Castration Resistant Metastatic Prostate Cancer; NSCLC | Dec 2027 |
| [64Cu]Cu-AKY-2519 anti-B7-H3 targeted imaging agent (copper-64 PET tracer) | B7H3 | Phase 1 | NSCLC | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07020117 | [225Ac]Ac-AKY-1189 | Phase 1 | Urothelial Carcinoma Bladder | Oncology | Dec 2027 |
| NCT07581184 | [225Ac]Ac-AKY-2519 | Phase 1 | Castration Resistant Metastatic Prostate Cancer | Oncology | Dec 2027 |
| NCT07887971 | [225Ac]Ac-AKY-2519 | Phase 1 | NSCLC | Oncology | Dec 2028 |
| NCT07887971 | [64Cu]Cu-AKY-2519 | Phase 1 | NSCLC | Oncology | Dec 2028 |
Cash and short-term investments of $517m on 2026-06-30; operating cash outflow about $91m a year; runway about 68 months at that burn, to Mar 2032
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
BicycleTx BioNTech SE Mabwell (Shanghai) Bioscience Tianjin ConjuStar Biologics Regeneron Pharmaceuticals Innate Pharma Astellas Samsung Bioepis Beijing Biotech Akeso
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.